Aadi Bioscience, Inc. announced the appointment of Mohammad Hirmand, M.D. to its Board of Directors. Dr. Hirmand has more than 20 years of biotechnology clinical development experience, and recently served as executive vice president and chief medical officer for Turning Point Therapeutics, which was acquired by Bristol Myers Squibb (BMS) for $4.1 billion in August 2022. Dr. Hirmand is a co-founder of Avenzo Therapeutics, and serves as its executive vice president and chief medical officer. Previously, Dr. Hirmand served as executive vice president and chief medical officer of Turning Point Therapeutics, where he was responsible for all development functions from December 2019 until its acquisition by BMS in August 2022.

Dr. Hirmand also served as chief medical officer of Peloton Therapeutics from 2017 until its acquisition by Merck & Co., Inc. in 2019. Dr. Hirmand served in various roles at Medivation, Inc., from 2007 to 2017, including most recently as its chief medical officer, through its acquisition by Pfizer Inc. He has also held clinical development roles of increasing responsibility at Nuvelo, Inc. (now ARCA Biopharma), SuperGen, Inc. (now Astex Pharmaceuticals, Inc.), Tularik, Inc. (now part of Amgen), and Theravance Biopharma, Inc. Dr. Hirmand received his M.D. from Harvard Medical School and his B.A. in Biological Sciences and Economics from Cornell University.